Humira Binding Assays

BioOutsource has extensive experience in the development, optimization and validation of a wide range of different types of binding assays and immunoassays and offers GCP, GLP and cGMP-compliant testing services in compliance with EMA and FDA guidelines to support the biopharmaceutical industry.
Using this experience, we have created a range of off-the-shelf binding assays, including Humira TNF-Alpha binding assay, Humira C1q binding assay, Humira FcRn binding assay and Humira Fc-Gamma Receptor binding assays to support process development, characterisation and biosimilarity studies.

Binding assays are employed to study a number of different features of Humira (adalimumab) and play a vital role in the development process and characterization and comparability studies, measuring the binding of Humira to TNF-Alpha as well as C1q, the Fc Gamma Receptors (FcR) and the neonatal Fc Receptor (FcRn). BioOutsource offers a comprehensive range of off-the-shelf generic binding methods to support the characterization of Humira (adalimumab) and performance of extensive comparability studies:

These methods have been developed using different platforms including ELISA, Electrochemiluminescence (MSD) or Surface Plasmon Resonance (SPR) and can be performed with a variety of different reporting mechanisms including affinity, on and off rates as well as relative binding using a totality of data evaluation approach to provide you with the comprehensive, industry-leading comparability reports required to understand all aspects of the performance of your Humira molecule.

BioOutsource offers cost-effective solutions to develop custom methods that are not currently in our portfolio please contact us to find out more.

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy